Vivos Therapeutics (VVOS) Competitors $3.38 -0.10 (-2.73%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VVOS vs. NSPR, OBIO, ZJYL, FONR, BDMD, EDAP, NTRB, APYX, VANI, and ICCMShould you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include InspireMD (NSPR), Orchestra BioMed (OBIO), Jin Medical International (ZJYL), Fonar (FONR), Baird Medical Investment (BDMD), EDAP TMS (EDAP), Nutriband (NTRB), Apyx Medical (APYX), Vivani Medical (VANI), and IceCure Medical (ICCM). These companies are all part of the "medical equipment" industry. Vivos Therapeutics vs. Its Competitors InspireMD Orchestra BioMed Jin Medical International Fonar Baird Medical Investment EDAP TMS Nutriband Apyx Medical Vivani Medical IceCure Medical Vivos Therapeutics (NASDAQ:VVOS) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership. Which has better valuation and earnings, VVOS or NSPR? Vivos Therapeutics has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVivos Therapeutics$14.39M1.77-$11.14M-$1.68-2.01InspireMD$7.07M14.05-$19.92M-$0.83-2.87 Do insiders & institutionals have more ownership in VVOS or NSPR? 26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 3.0% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 29.7% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer VVOS or NSPR? Vivos Therapeutics currently has a consensus price target of $4.92, indicating a potential upside of 45.25%. InspireMD has a consensus price target of $4.50, indicating a potential upside of 89.08%. Given InspireMD's stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Vivos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50InspireMD 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VVOS or NSPR more profitable? Vivos Therapeutics has a net margin of -99.49% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vivos Therapeutics-99.49% -232.76% -84.30% InspireMD -413.96%-69.42%-57.68% Does the media favor VVOS or NSPR? In the previous week, Vivos Therapeutics had 1 more articles in the media than InspireMD. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for InspireMD. Vivos Therapeutics' average media sentiment score of 1.19 beat InspireMD's score of 0.26 indicating that Vivos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InspireMD 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, VVOS or NSPR? Vivos Therapeutics has a beta of 7.02, meaning that its stock price is 602% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. SummaryInspireMD beats Vivos Therapeutics on 9 of the 16 factors compared between the two stocks. Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VVOS vs. The Competition Export to ExcelMetricVivos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.40M$2.51B$5.65B$10.30BDividend YieldN/A56.32%5.68%4.61%P/E Ratio-2.0123.2275.8526.09Price / Sales1.77574.52514.78169.46Price / CashN/A174.1537.5661.52Price / Book2.515.1612.886.30Net Income-$11.14M$32.95M$3.29B$271.03M7 Day Performance1.35%0.15%-0.25%-0.14%1 Month Performance-26.89%5.11%3.88%6.44%1 Year Performance4.48%1.29%68.42%28.85% Vivos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVOSVivos Therapeutics2.7839 of 5 stars$3.39-2.7%$4.92+45.2%+14.5%$25.40M$14.39M-2.01160Positive NewsNSPRInspireMD3.445 of 5 stars$2.41+1.3%$4.50+86.7%-12.0%$100.55M$7.07M-3.2150Positive NewsOBIOOrchestra BioMed2.9749 of 5 stars$2.53-2.7%$13.50+433.6%-47.5%$97.77M$2.94M-1.384Positive NewsZJYLJin Medical InternationalN/A$0.62-0.9%N/A-80.1%$97.23M$23.50M0.00245Positive NewsGap UpFONRFonar1.2323 of 5 stars$15.47-0.3%N/A-11.9%$95.91M$102.88M12.38480Earnings ReportUpcoming EarningsBDMDBaird Medical InvestmentN/A$2.66+2.3%N/AN/A$95.04MN/A0.00N/APositive NewsGap DownEDAPEDAP TMS2.2846 of 5 stars$2.33-3.3%$8.50+264.8%-16.4%$87.12M$69.18M-3.82230NTRBNutriband2.9421 of 5 stars$7.15+6.1%$13.00+81.8%+8.5%$86.05M$2.58M-2.4910APYXApyx Medical2.3507 of 5 stars$2.13flatN/A+72.3%$80.55M$46.51M-4.73270Positive NewsVANIVivani Medical3.4086 of 5 stars$1.21-4.7%$4.00+230.6%+22.5%$71.68MN/A-2.6920News CoveragePositive NewsICCMIceCure Medical2.3911 of 5 stars$1.02-5.6%$2.39+133.8%+71.3%$70.07M$3.29M-6.3860 Related Companies and Tools Related Companies InspireMD Competitors Orchestra BioMed Competitors Jin Medical International Competitors Fonar Competitors Baird Medical Investment Competitors EDAP TMS Competitors Nutriband Competitors Apyx Medical Competitors Vivani Medical Competitors IceCure Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VVOS) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
